Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models

ConferenceATNM-400Positive

AI Analysis

Summary

Actinium Pharmaceuticals presented data on ATNM-400 at SNMMI 2026 demonstrating the drug's ability to overcome resistance to all three approved androgen receptor inhibitors in prostate cancer models with flexible and well-tolerated dosing.

Outcome Details

Oral presentation at SNMMI 2026 highlighting ATNM-400 overcoming resistance to approved androgen receptor inhibitors with flexible, well-tolerated dosing

Importance:5/10

Sentiment:

0.60

prostate cancerandrogen receptor inhibitordrug resistanceSNMMI 2026clinical data

Related Companies

$ATNM

Read the original article

Published by yahoo_finance on June 3, 2026 11:25 AM

Read Original